




UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: December 14, 2023  
Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:01 PM EST		
A. Minutes from previous meetings	G. Shutzberg	Review of Minutes from September 14, 2023	Minutes reviewed, approved	Yes
<b>B. Formulary Review - New Drugs</b>				
	M. Reisman	<b>Litfulo</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	<b>Miebo</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	<b>Suflave</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	<b>Vanflyta</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Blosser	<b>Ngenla</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	Dr. Pappalardo asked is Ngenla statistically superior? Christina said that when looking at a 12 month study, it was non-inferior to Genotropin.		
	Comment:	Arethusa Kirk asked what is the step that needs to be taken with daily dosing to prove that long acting is necessary? Christina answered it would either be a failure to a somatropin product or if there is an intolerance or contraindication to the somatropin products. If there is a reason why the patient is unable to take the daily injections, then they would need a provider rationale within that section of the step therapy. The step therapy is consistent with the other long-acting products.		
	C. Blosser	<b>Brenzavvy</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Blosser	<b>Inpefa</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Blosser	<b>Xdemvy</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
<b>C. Formulary Review - PDL Modifications</b>				
	M. Reisman	<b>Confirm Review of PDL Modifications Grid</b>	<b>Yes/No</b>	<b>Yes</b>
		Recommendation: • <b>Amjevita high concentration</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>adalimumab-adbm</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>adalimumab-fkjp</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Dupixent</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Amovig</b> : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Ajovy</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Ubrelyv</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>naloxone OTC/Narcan OTC</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>moxifloxacin 0.5% ophthalmic solution</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Rykindo</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Abilify Asimtuffi</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>solifenacin succinate oral tablet</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>tropium chloride oral tablet</b> : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>tolterodine tartrate ER oral capsule</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Crotan 10% topical lotion</b> : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Udenyca</b> : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Ziextenzo</b> : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>Adderall XR</b> : Move to non-preferred with prior authorization in the NY EPP market	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • <b>amphetamine/dextroamphetamine ER</b> : Move to preferred in the NY EPP market	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	Paula Miller stated generic Adderall has been not available, are there instances where we would make formulary changes due to the non-availability? Maria Theys answered, we are seeing sporadic shortages of Adderall products and we are handling these issues as they arise, on a market to market basis.		

D. Formulary Review - New Drugs- Medical				
C. Blosser	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes	
	<b>Beyfortus</b>			
	Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Brixadi</b>			
	Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Elevidys</b>			
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Elfabrio</b>			
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Epkinly</b>			
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Roctavian</b>			
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Rystiggo</b>			
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Talvey</b>			
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Vyjuvek</b>			
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Xacduro</b>			
	Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
	<b>Ycanth</b>			
	Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0	
E. Formulary Review - Drugs Evaluated Per Grid				
C. Blosser	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	10:0	
F. Clinical Guidelines				
C. Blosser	Clinical Guideline Review			
	Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	10:0	
	Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	10:0	
	Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	10:0	
G. Annual PDL Ratification				
G. Shutzberg	Approve Preferred Drug Lists (PDLs) for each market, including the Wrap Plan File	Motion made, seconded, and carried to accept recommendation	10:0	
H. Quality Monitoring				
L. Charlton/ M. Reisman	Confirm Review of Quality Data	Yes/No	Yes	
L. Charlton	DUR Review			
M. Reisman	Drug Recalls – 3rd Quarter 2023			
M. Reisman	Top 25 Drugs by Spend and Volume – 3rd Quarter 2023			
M. Reisman	Top 10 Drugs Requested - Approvals and Denials – 3rd Quarter 2023			
M. Reisman	Grievances and Appeals Data – 3rd Quarter 2023			
M. Reisman	Inter-Rater Reliability (IRR) – 3rd Quarter 2023 • Pharmacists			
M. Reisman	Inter-Rater Reliability (IRR) – 4th Quarter 2023 • Medical Directors			
I. Additional Comments/Questions				
Comment:	Paula Miller asked if Levemir is a preferred product on any formularies? Maria Theys replied, Levemir is non-preferred.			
Adjournment				
G. Shutzberg	6:30PM EST			
Proposed 2024 P&T Dates				
March 7th	June 6th	September 12th	December 12th	
Respectfully Submitted to the Committee,				
				
James P. Hancovsky, M.S.I.A., R.Ph. Chief Pharmacy Officer, UHC C&S				